Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will CE's net leverage ratio exceed 7.0x at any quarter-end through Q4 2026?
Current Prediction
Why This Question Matters
Net leverage above 7.0x would indicate covenant proximity, would constrain refinancing flexibility, and would shift FUNDING_FRAGILITY from ELEVATED toward STRAINED. CE's revolver was extended to 2030 in Aug 2025, which signaled bank confidence at senior level despite junk rating. A leverage breach to 7.0x against extended bank covenants would force corrective action — either accelerated divestitures, equity issuance, or bond retap at higher spread. This is the inverse of the recovery thesis; a clean YE2026 leverage at 5.0-5.5x would confirm execution. Stress-scanner and roadkill-radar both flag 7.0x as the critical threshold.
Prediction Distribution
Individual Predictions(9 runs)
Math: $11B net debt / 7.0x = $1.57B EBITDA TTM. Current TTM ~$1.7-1.9B. To breach, EBITDA needs to fall to $1.5B sustained — requires 2 quarters at $350-400M each. Plausible but tail scenario. Cycle extension scenario (10-15%) is the primary path to this outcome. Net debt direction: declining $650-750M annually from FCF, which actively shrinks leverage even at flat EBITDA. With FCF discipline holding, leverage probably moves to 5.0-5.5x by YE2026 in base case. 4-quarter window adds chances for transient EBITDA dip. ~15-20%.
Bank confidence at senior level (revolver extension to 2030) implies leverage trajectory is acceptable. For 7.0x breach we need EBITDA collapse + working capital drain or M&A surprise. Mgmt has eliminated dividend, no buybacks, divestitures are net-debt-reducing. Most paths to leverage spike are blocked. ~15%.
The committee anchors structural-decline counterfactual at 8-12% with mid-cycle EBITDA $1.8-2.0B. If structural, leverage walks to 5.5-6.1x not 7.0x. So even structural decline doesn't directly produce 7.0x without compounding factors (impairment + working capital + cycle extension). 4-quarter window: any-quarter probability 15-20% given compounding tail. ~18%.
Quarterly TTM EBITDA can spike low transiently due to seasonal Q1 + working capital. Combined with any large impairment (Sadara-type EM goodwill), single-quarter print at 7.0x is plausible. Mgmt would aggressively message past optical leverage. ~20%.
5.5-6.5x current. Cycle-extension scenario probability ~10-15%. EM impairment probability material (mgmt strategic review). Adding factors: net 18%.
Active deleveraging from FCF is the dominant trajectory. ~15-18% probability of leverage breach assumes most factors aligning negatively. Base case clearly trends lower. ~16%.
Cycle extension prob 10-15%. EM impairment overlay. 4-quarter chances. ~18%.
Bank confidence + active deleveraging + dividend cut all point to leverage decline. 7.0x is tail event. ~15%.
Compounding scenarios: cycle extension + impairment + working capital build. Probability ~15-20%. ~18%.
Resolution Criteria
Resolves YES if CE's reported net debt / trailing-twelve-month adjusted EBITDA ratio at any quarter-end (Q1, Q2, Q3, or Q4 2026) exceeds 7.0x, as disclosed in earnings release, investor presentation, or 10-Q filing. Resolves NO if all four quarter-ends print at or below 7.0x.
Resolution Source
CE quarterly earnings releases, investor presentations, 10-Q and 10-K filings
Source Trigger
Net leverage >7.0x
Full multi-lens equity analysis